Five different activities hidden under one word: research
An individual reviewing literature or publishing a mechanistic hypothesis is not doing the same thing as collecting coded observational records, assigning a medical intervention, administering a new investigational substance, or marketing a medicine. Those activities differ in both scientific inference and regulatory consequences. The starting step is to specify the article, intended purpose, intervention, population, sponsor and data handling. F01F10F25
One project may contain several of those activities. For instance, a community might publicly discuss a research question, privately maintain an observational registry, and later consider a trial. The original discussion and registry do not automatically authorize the trial. A serious initiative should give investigators a classification and escalation process rather than an all-purpose label.
The proposal therefore distinguishes a publication right, an analytical data-participation right, an investigational study application pathway, and lawful supply or marketing permissions. A participant signature on this website belongs to civic advocacy, not to any research protocol. That distinction is a workflow boundary, not a reason to avoid seeking reform.
IND sponsor and investigational drug analysis
21 CFR §312.3 expressly permits individual sponsors, and §312.2 addresses application and exemptions. A sponsor-investigator may initiate and personally conduct an investigation but must satisfy the rules relevant to that role. The fact that an applicant is not attached to a hospital is not by itself the end of the analysis; neither is the applicant's declaration of personal risk. F01F02
Where an IND is required, the general process under §312.40 includes a period before the clinical investigation may begin and the possibility of clinical holds. Additional sponsor responsibilities arise from the investigational product, safety reporting, investigator selection, monitoring, quality and records. The regulatory map should identify who performs each duty even when the work is distributed. F03F04F05F06
A lawful research-supply pathway also implicates manufacturing, identity, contamination, labeling, accountability, storage, distribution, and disposal. A pure chemical compound by mass spectrometry is not by that fact sterile, clinically suitable, or legally authorized. A proposed access statute needs a technically sound product-quality branch, or scientific freedom may be undermined by uninterpretable exposure and avoidable harm.
Human-subjects review: FDA and the Common Rule
FDA-governed human investigations can implicate informed consent and IRB provisions, while HHS's Common Rule applies through its own coverage conditions, including federally conducted or supported research and participating institutional commitments. They are overlapping but not identical regulatory pathways. Staff should not say every purely private human activity automatically comes under 45 CFR Part 46, or that the absence of Common Rule coverage means no FDA rule applies. F07F09F10
Expedited IRB review and specified exemptions are already part of existing law. The proposed Act should not falsely portray them as new inventions. Instead, an independent-study service could publish a practical application map, support access to duly qualified external IRBs, help investigators document why a pathway applies, and fund evaluations of review cost and delay. F09F24
Where a proposed reform uses the phrase 'proportionate review,' it must identify who classifies risk, which review may be expedited, what may not be waived, and how decisions are preserved for audit. Transparent eligibility criteria and written reasons offer a way to protect institutional independence while giving smaller teams meaningful procedures.
Clinical trials, expanded access and Right to Try
Interventional studies assign interventions to assess defined outcomes; observational studies collect information without assigning interventions for research. Expanded access is a treatment access mechanism for eligible patients outside ordinary trial enrollment under defined criteria. Right to Try is a different narrow statutory route. These are not interchangeable rights and should appear in a congressional comparison table. F11F22F23F25
The historical Right to Try provision demonstrates that Congress can create targeted legal alternatives, but a broad healthy-adult self-directed investigational program would require a fresh policy decision. It must define whether the law authorizes a study, allows supply, changes informed consent, alters FDA review, protects qualified clinicians, or does several of those things together.
A serious bill should also recognize that a lawful pathway does not necessarily compel a private manufacturer to provide an investigational product. Material access can depend on price, supply quality, contracts, and intellectual property. Congress should study these bottlenecks rather than promise that a statute will force all suppliers to cooperate.
Decentralization is a delivery mechanism, not a legal loophole
FDA's 2024 decentralized trial guidance addresses study activities conducted through telehealth, home visits and local health care providers. The 2025 E6(R3) GCP guidance emphasizes quality-by-design and modern risk-based conduct. Those advances provide a framework for community access but do not erase investigator qualifications or sponsor obligations. F18F19
Remote participation may reduce geographical burden, but published reviews do not show that every decentralized method improves recruitment, retention or cost. A 2021 systematic review found insufficient evidence to confirm which DCT methods most improve those outcomes, and subsequent reviews identify recruitment bias, retention and reporting gaps. The legislative pilot must measure actual effects instead of treating remote access as self-evident success. P01P03P05
The practical mapping exercise is to list every research event: informed consent, verification, enrollment, investigational delivery, clinical observations, biological samples, adverse events, withdrawals, privacy access, statistical analysis and public results. Assign a responsible person and a supported communication channel to each event; require documented escalation when it fails.